UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  September 13, 2017

 

Streamline Health Solutions, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-28132

 

31-1455414

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

1230 Peachtree Street, NE, Suite 600

Atlanta, GA 30309

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (404) 446-2052

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company                                              o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       o

 

 

 



 

Item 2.02.                                        Results of Operations and Financial Condition.

 

On September 13, 2017, Streamline Health Solutions, Inc. (the “Company”) issued a press release announcing second quarter 2017 financial results.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information contained in this Item 2.02, as well as Exhibit 99.1 referenced herein, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, unless the Company expressly so incorporates such information by reference.

 

Item 9.01.                                        Financial Statements and Exhibits.

 

(d)  Exhibits.

 

EXHIBIT

 

 

NUMBER

 

DESCRIPTION

 

 

 

99.1

 

Press release, dated September 13, 2017, regarding Second Quarter 2017 Financial Results.

 

2



 

INDEX TO EXHIBITS

 

EXHIBIT

 

 

NUMBER

 

DESCRIPTION

 

 

 

99.1

 

Press release, dated September 13, 2017, regarding Second Quarter 2017 Financial Results.

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Streamline Health Solutions, Inc.

 

 

 

 

 

 

 

 

Date:

September 13, 2017

By:

/s/ Nicholas A. Meeks

 

 

Name:

Nicholas A. Meeks

 

 

Title:

Senior Vice President and Chief Financial Officer

 

4


Exhibit 99.1

 

 

News Release

 

STREAMLINE HEALTH® REPORTS SECOND QUARTER 2017 REVENUES OF $5.9 MILLION; ($1.1 MILLION) NET LOSS; ADJUSTED EBITDA OF $0.5 MILLION

 

Total First Half Fiscal 2017 Revenue $11.8 Million; Net Loss ($3.1 million)

 

Break-Even Adjusted EBITDA

 

Atlanta, GA — September 13, 2017 — Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of integrated solutions, technology-enabled services and analytics supporting revenue cycle optimization for healthcare enterprises, today announced financial results for the second quarter and first half of fiscal 2017, which ended July 31, 2017.

 

Revenues for the three-month period ended July 31, 2017 decreased approximately 20% to $5.9 million over the revenues for the three-month period ended July 31, 2016 of $7.4 million, which included $1.0 million of perpetual license revenue.  Revenue was down approximately 7% year-over-year in the second quarter of fiscal 2017 when excluding the perpetual license revenue for the same period in 2016 ($5.9 million as compared to $6.4 million).  Recurring revenue comprised 82% of total revenue in the quarter. Revenues for the first six months of fiscal year 2017 were $11.8 million, down approximately 16% as compared to $14.1 million in the first half of fiscal 2016.  Revenue for the first six months of fiscal 2017 was down approximately 9% from the same period in 2016 when excluding the perpetual license revenue for the same period in 2016.

 

Net loss for the second quarter of fiscal 2017 was $(1.1 million) as compared to a ($.7 million) net loss in the same period a year ago.  Net loss for the six months of fiscal 2017 was ($3.1 million) as compared to ($2.2 million) net loss for the same period in 2016.

 

Adjusted EBITDA for the second quarter of fiscal 2017 was $0.5 million, down from $1.6 million in the second quarter of 2016. Adjusted EBITDA for the first six months of fiscal 2017 was break-even, as compared to $2.2 million in the first half of fiscal 2016.

 

“Our second quarter financial performance started to show some of the promise we envisioned when we refocused our efforts to the middle of the revenue cycle.  During the quarter, we sold auditing services to four new clients such as Iora Health headquartered in Boston, Union General in Louisiana and St. Francis Medical Center in Missouri,” stated David Sides, President and Chief Executive Officer, Streamline Health.  “Although these new contracts are small in terms of initial revenue contribution, we believe there is the opportunity for growth within each of these as we bring new technology to the relationships. Our pipeline for our new Streamline Health eValuator™ remains robust.  We closed a new client after the second quarter ended which we believe will be one of many throughout the second half of our fiscal year. We continue to believe that we will generate incremental growth in our bookings in the second half of this year and into 2018.

 



 

Our balance sheet was mostly unchanged from the first quarter of this year as our cash on hand decreased the same amount as our debt.  Going forward, we do not foresee paying down our debt at such an accelerated pace; rather we plan to grow our cash on hand.”

 

Highlights for the three months ended July 31, 2017 included:

 

·                  Revenue for the second quarter 2017 was $5.9 million;

·                  Net loss for the second quarter 2017 was $(1.1 million);

·                  Adjusted EBITDA for the second quarter 2017 was $0.5 million;

·                  New sales bookings for the quarter were $1.1 million; and

·                  Backlog at the end of the quarter was $46.3 million.

 

Conference Call Information

 

An accompanying conference call will be hosted by David Sides, Chief Executive Officer and Nicholas Meeks, Senior Vice President and Chief Financial Officer. The call will be held at 9:00 AM ET, on Thursday, September 14, 2017 and will be accompanied by a live webcast. Please refer to the information below for conference call dial-in information and webcast registration.

 

Conference Date: September 14, 2017, 9:00 AM ET

 

Webcast Registration: Click Here

 

Conference Dial-In: 866-564-2842

 

Conference Passcode: 5680323

 

Conference Call Name: Streamline Health Solutions Second Quarter 2017 Results Call

 

Following the call, a replay will be available on the Company’s website, www.streamlinehealth.net, in the Investor Relations section.

 

*Non-GAAP Financial Measures

 

Streamline Health reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline Health’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health’s management believes that this measure provides useful supplemental information regarding the performance of Streamline Health’s business operations.

 

Streamline Health defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, professional and advisory fees, and internal direct costs incurred to complete transactions. A table illustrating this measure is included in this press release.

 

About Streamline Health

 

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge — providing actionable insights that support revenue cycle optimization for healthcare enterprises.   We deliver integrated solutions and analytics that enable providers to drive reimbursement in a value-based world. We share a common calling and commitment to advance the quality of life and the quality of healthcare — for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

 



 

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

 

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s estimates of future revenue, backlog, results of investments in sales and marketing, success of future products and related expectations and assumptions.  These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to control costs, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, and the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

 

Company Contact:

Randy Salisbury

SVP, Chief Marketing Officer

(404) 229-4242

randy.salisbury@streamlinehealth.net

 



 

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

July 31,

 

July 31,

 

 

 

2017

 

2016

 

2017

 

2016

 

Revenues:

 

 

 

 

 

 

 

 

 

Systems sales

 

$

328,692

 

$

1,364,771

 

$

707,415

 

$

1,876,038

 

Professional services

 

571,812

 

548,080

 

991,847

 

1,238,695

 

Audit Services

 

291,441

 

 

639,460

 

 

Maintenance and support

 

3,278,562

 

3,732,488

 

6,633,334

 

7,488,041

 

Software as a service

 

1,442,652

 

1,728,724

 

2,867,784

 

3,438,510

 

Total revenues

 

5,916,159

 

7,374,063

 

11,839,840

 

14,041,284

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Cost of systems sales

 

596,799

 

671,631

 

1,162,850

 

1,417,115

 

Cost of professional services

 

543,206

 

529,024

 

1,258,421

 

1,167,788

 

Cost of Audit Services

 

391,439

 

 

832,078

 

 

Cost of maintenance and support

 

768,140

 

835,353

 

1,574,662

 

1,693,171

 

Cost of software as a service

 

285,832

 

455,370

 

625,208

 

939,613

 

Selling, general and administrative

 

2,790,171

 

3,341,949

 

6,163,699

 

6,940,790

 

Research and development

 

1,495,972

 

2,108,567

 

3,052,910

 

3,830,754

 

Total operating expenses

 

6,871,559

 

7,941,894

 

14,669,828

 

15,989,231

 

Operating loss

 

(955,400

)

(567,831

)

(2,829,988

)

(1,947,947

)

Other expense (income):

 

 

 

 

 

 

 

 

 

Interest expense

 

(120,377

)

(120,014

)

(247,645

)

(282,026

)

Miscellaneous income (expenses)

 

(19,681

)

(44,756

)

(57,725

)

21,466

 

Loss before income taxes

 

(1,095,458

)

(732,601

)

(3,135,358

)

(2,208,507

)

Income tax benefit (expense)

 

(2,607

)

(1,701

)

(5,215

)

(3,402

)

Net loss

 

$

(1,098,065

)

$

(734,302

)

$

(3,140,573

)

$

(2,211,909

)

Less: deemed dividends on Series A Preferred Shares

 

 

(418,506

)

 

(803,225

)

Net loss attributable to common shareholders

 

$

(1,098,065

)

$

(1,152,808

)

$

(3,140,573

)

$

(3,015,134

)

Basic net loss per common share

 

$

(0.06

)

$

(0.06

)

$

(0.16

)

$

(0.16

)

Number of shares used in basic per common share computation

 

19,834,859

 

19,791,805

 

19,765,125

 

19,393,547

 

Diluted net loss per common share

 

$

(0.06

)

$

(0.06

)

$

(0.16

)

$

(0.16

)

Number of shares used in diluted per common share computation

 

19,834,859

 

19,791,805

 

19,765,125

 

19,393,547

 

 



 

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

Assets

 

 

 

July 31,

 

January 31,

 

 

 

2017

 

2017

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

2,916,459

 

$

5,654,093

 

Accounts receivable, net of allowance for doubtful accounts of $286,084 and $198,449, respectively

 

4,621,331

 

4,489,789

 

Contract receivables

 

69,625

 

466,423

 

Prepaid hardware and third party software for future delivery

 

5,858

 

5,858

 

Prepaid client maintenance contracts

 

710,309

 

595,633

 

Other prepaid assets

 

861,300

 

732,496

 

Other current assets

 

665

 

439

 

Total current assets

 

9,185,547

 

11,944,731

 

 

 

 

 

 

 

Non-current assets:

 

 

 

 

 

Property and equipment:

 

 

 

 

 

Computer equipment

 

3,081,856

 

3,110,274

 

Computer software

 

831,242

 

827,642

 

Office furniture, fixtures and equipment

 

683,443

 

683,443

 

Leasehold improvements

 

729,348

 

729,348

 

 

 

5,325,889

 

5,350,707

 

Accumulated depreciation and amortization

 

(3,814,938

)

(3,447,198

)

Property and equipment, net

 

1,510,951

 

1,903,509

 

 

 

 

 

 

 

Capitalized software development costs, net of accumulated amortization of $17,688,421 and $16,544,797 respectively

 

4,285,069

 

4,584,245

 

Intangible assets, net of accumulated amortization of $6,473,451 and $5,807,338, respectively

 

6,330,485

 

6,996,599

 

Goodwill

 

15,537,281

 

15,537,281

 

Other

 

636,232

 

672,133

 

Total non-current assets

 

28,300,018

 

29,693,767

 

 

 

$

37,485,565

 

$

41,638,498

 

 



 

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

Liabilities and Stockholders’ Equity

 

 

 

 

July 31,

 

January 31,

 

 

 

2017

 

2017

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

1,566,454

 

$

1,116,525

 

Accrued compensation

 

481,528

 

496,706

 

Accrued other expenses

 

188,172

 

484,391

 

Current portion of term loan

 

596,980

 

655,804

 

Deferred revenues

 

9,298,192

 

9,916,454

 

Current portion of capital lease obligations

 

23,188

 

91,337

 

Total current liabilities

 

12,155,214

 

12,761,217

 

 

 

 

 

 

 

Non-current liabilities:

 

 

 

 

 

Term loan, net of deferred financing cost of $181,477 and $199,211, respectively

 

4,164,381

 

4,883,286

 

Warrants liability

 

360

 

46,191

 

Royalty liability

 

2,423,602

 

2,350,754

 

Lease incentive liability

 

311,585

 

339,676

 

Deferred revenues, less current portion

 

363,910

 

568,515

 

Total non-current liabilities

 

7,263,838

 

8,188,422

 

Total liabilities

 

19,419,052

 

20,949,639

 

 

 

 

 

 

 

Series A 0% Convertible Redeemable Preferred stock, $.01 par value per share, $8,849,985 redemption value, 4,000,000 shares authorized, 2,949,995 issued and outstanding, net of unamortized preferred stock discount of $0

 

8,849,985

 

8,849,985

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Common stock, $.01 par value per share, 45,000,000 shares authorized, 19,962,672 and 19,695,391 shares issued and outstanding, respectively

 

199,627

 

196,954

 

Additional paid in capital

 

81,183,325

 

80,667,771

 

Accumulated deficit

 

(72,166,424

)

(69,025,851

)

Total stockholders’ equity

 

9,216,528

 

11,838,874

 

 

 

$

37,485,565

 

$

41,638,498

 

 



 

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

 

Six Months Ended July 31,

 

 

 

2017

 

2016

 

Operating activities:

 

 

 

 

 

Net loss

 

$

(3,140,573

)

$

(2,211,909

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

 

Depreciation

 

403,090

 

630,706

 

Amortization of capitalized software development costs

 

1,143,624

 

1,425,962

 

Amortization of intangible assets

 

666,114

 

650,892

 

Amortization of other deferred costs

 

161,064

 

115,113

 

Valuation adjustment for warrants liability

 

(45,831

)

(61,856

)

Share-based compensation expense

 

555,229

 

909,411

 

Other valuation adjustments

 

86,192

 

83,937

 

Loss on disposal of property and equipment

 

(720

)

567

 

Provision for accounts receivable

 

166,170

 

88,472

 

Changes in assets and liabilities, net of assets acquired:

 

 

 

 

 

Accounts and contract receivables

 

99,086

 

357,774

 

Other assets

 

(333,401

)

(214,327

)

Accounts payable

 

449,929

 

(403,600

)

Accrued expenses

 

(352,132

)

(472,420

)

Deferred revenues

 

(822,867

)

(759,411

)

Net cash (used in) provided by operating activities

 

(965,026

)

139,311

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

Purchases of property and equipment

 

(9,812

)

(60,518

)

Capitalization of software development costs

 

(844,448

)

(936,560

)

Net cash used in investing activities

 

(854,260

)

(997,078

)

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

Principal repayments on term loan

 

(813,197

)

(2,075,172

)

Principal payments on capital lease obligation

 

(68,149

)

(438,962

)

Proceeds from exercise of stock options and stock purchase plan

 

 

14,793

 

Payments related to settlement of employee shared-based awards

 

(37,002

)

(11,702

)

Net cash used in financing activities

 

(918,348

)

(2,511,043

)

Decrease in cash and cash equivalents

 

(2,737,634

)

(3,368,810

)

Cash and cash equivalents at beginning of period

 

5,654,093

 

9,882,136

 

Cash and cash equivalents at end of period

 

$

2,916,459

 

$

6,513,326

 

 



 

STREAMLINE HEALTH SOLUTIONS, INC.

Backlog

(Unaudited)

Table A

 

 

 

 

July 31,
2017

 

January 31, 
2017

 

July 31,
2016

 

Company Proprietary Software

 

$

11,458,000

 

$

11,504,000

 

$

15,133,000

 

Third Party Hardware and Software

 

50,000

 

150,000

 

200,000

 

Professional Services

 

3,517,000

 

4,068,000

 

5,563,000

 

Audit Services

 

1,454,000

 

1,847,000

 

 

Maintenance and Support

 

16,583,000

 

19,193,000

 

19,569,000

 

Software as a Service

 

13,300,000

 

13,861,000

 

13,177,000

 

Total

 

$

46,362,000

 

$

50,623,000

 

$

53,642,000

 

 

STREAMLINE HEALTH SOLUTIONS, INC.

New Bookings

(Unaudited)

Table B

 

 

 

Three Months Ended

 

 

 

July 31, 2017

 

 

 

Value

 

% of Total 
Bookings

 

Streamline Health Software licenses

 

$

59,000

 

5

%

Software as a service

 

47,000

 

4

%

Maintenance and support

 

122,000

 

11

%

Audit Services

 

108,000

 

10

%

Professional services

 

777,000

 

70

%

Hardware & third party software

 

 

0

%

Total bookings

 

$

1,113,000

 

100

%

 



 

Reconciliation of Non-GAAP Financial Measures

(Unaudited)

Table C

 

This press release contains a non-GAAP financial measure under the rules of the U.S. Securities and Exchange Commission for adjusted EBITDA. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget. Non-GAAP financial measures are used by Streamline Health’s management in its operating and financial decision-making because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, the Company believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a) understand and evaluate current operating performance and future prospects in the same manner as management does and (b) compare in a consistent manner the Company’s current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. The Company’s management compensates for these limitations by considering the Company’s financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release. Streamline Health defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, professional and advisory fees, and internal direct costs incurred to complete transactions.

 

Reconciliation of net earnings (loss) to non-GAAP adjusted EBITDA (in thousands)

 

 

 

Three Months Ended,

 

Six Months Ended,

 

Adjusted EBITDA Reconciliation

 

July 31,
2017

 

July 31,
2016

 

July 31,
2017

 

July 31,
2016

 

Net loss

 

$

(1,098

)

$

(734

)

$

(3,134

)

$

(2,212

)

Interest expense

 

120

 

120

 

248

 

282

 

Income tax expense

 

3

 

2

 

5

 

3

 

Depreciation

 

200

 

310

 

403

 

631

 

Amortization of capitalized software development costs

 

572

 

710

 

1,144

 

1,426

 

Amortization of intangible assets

 

333

 

325

 

666

 

651

 

Amortization of other costs

 

43

 

36

 

126

 

80

 

EBITDA

 

173

 

769

 

(549

)

861

 

Share-based compensation expense

 

288

 

432

 

555

 

909

 

(Gain) Loss on disposal of fixed assets

 

 

 

(1

)

1

 

Associate severances and other costs relating to transactions or corporate restructuring

 

 

110

 

 

110

 

Non-cash valuation adjustments to assets and liabilities

 

23

 

14

 

40

 

22

 

Transaction related professional fees, advisory fees and other internal direct costs

 

 

236

 

 

255

 

Adjusted EBITDA

 

$

484

 

$

1,561

 

$

45

 

$

2,158

 

Adjusted EBITDA Margin(1)

 

8

%

21

%

%

15

%

Adjusted EBITDA per diluted share

 

 

 

 

 

 

 

 

 

Loss per share — diluted

 

$

(0.06

)

$

(0.06

)

$

(0.16

)

$

(0.16

)

Adjusted EBITDA per adjusted diluted share (2)

 

$

0.02

 

$

0.07

 

$

 

$

0.10

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted average shares

 

19,834,859

 

19,791,805

 

19,765,125

 

19,393,547

 

    Includable incremental shares — adjusted EBITDA (3)

 

3,378,484

 

3,376,285

 

3,322,319

 

3,313,870

 

Adjusted diluted shares

 

23,213,343

 

23,168,090

 

23,087,444

 

22,707,417

 

 


(1)                                 Adjusted EBITDA as a percentage of GAAP revenues.

(2)                                 Adjusted EBITDA per adjusted diluted share for the Company’s common stock is computed using the more dilutive of the two-class method or the if-converted method.

(3)                                 The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed.